{
    "eid": "2-s2.0-85084327993",
    "title": "Cost-Effectiveness of Primary HPV Screening Strategies and Triage With Cytology or Dual Stain for Cervical Cancer",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "biomarkers",
        "cancer screening",
        "cervical cancer",
        "cost-effectiveness analysis",
        "human papillomavirus DNA tests"
    ],
    "authors": [
        "Tanitra Tantitamit",
        "Nipon Khemapech",
        "Piyalamporn Havanond",
        "Wichai Termrungruanglert"
    ],
    "citedby-count": 2,
    "ref-count": 42,
    "ref-list": [
        "Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities",
        "Low coverage and disparities of breast and cervical cancer screening in Thai women: analysis of national representative household surveys",
        "Effective screening programmes for cervical cancer in low- and middle-income developing countries",
        "Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand",
        "P16(INK4a)/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya",
        "Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial",
        "Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study",
        "p16/Ki-67 Dual stain cytology for detection of cervical precancer in HPV-positive women",
        "Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results",
        "Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data",
        "Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand",
        "Diagnostic performance of dual-staining cytology for cervical cancer screening: a systematic literature review",
        "Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology",
        "Guidelines for the treatment of recurrent and metastatic cervical cancer",
        "Benefits and costs of using HPV testing to screen for cervical cancer",
        "Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries",
        "Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial",
        "Triage of HPV positive women in cervical cancer screening",
        "The ATHENA human papillomavirus study: design, methods, and baseline results",
        "Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study",
        "Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy",
        "Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients",
        "Prevalence of human papillomavirus types in women screened by cytology in Germany",
        "Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany\u2014experience over 3 years",
        "Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management",
        "Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data",
        "Natural history of dysplasia of the uterine cervix",
        "The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice",
        "IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia",
        "Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women",
        "Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance",
        "Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model",
        "Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis",
        "Survival of cervical cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005800",
            "affilname": "Faculty of Medicine, Srinakharinwirot University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005800",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Roche"
    ]
}